Altimmune ALT
NASDAQ ALT
$1.93 -0.01 (-0.52%)
At close: Nov 11, 2026 · 4:00 PM EST

Altimmune (ALT) Restructuring Costs (2015)

Updated

Altimmune (ALT) recorded Restructuring Costs of $26,886 in Q4 2015, down 93.6% from the prior quarter.

Analysis

Altimmune (ALT) Restructuring Costs (2015) Analysis & Trends

For FY2015, Altimmune reported Restructuring Costs of $2.55 million.

  • Per Business Quant, the preceding three quarters came in at $422,482 (Q3 2015), $35,982 (Q2 2015) and $2.06 million (Q1 2015).
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Eli Lilly 1,348.13 Bn 1,321.74 Bn 20.46 Bn
2 Johnson & Johnson 675.90 Bn 595.76 Bn 17.30 Bn
3 AbbVie 519.45 Bn 487.50 Bn 13.12 Bn
4 Merck 364.95 Bn 327.95 Bn 13.19 Bn
5 Novartis Ag 311.58 Bn 285.16 Bn -
6 Astrazeneca 289.34 Bn 262.94 Bn 13.26 Bn
7 Amgen 251.64 Bn 203.30 Bn 7.58 Bn
8 Gilead Sciences 212.05 Bn 187.07 Bn 6.73 Bn
9 Pfizer 167.35 Bn 115.00 Bn 12.56 Bn
10 Altimmune 377.28 Mn -764.94 Mn -
Historic Data

Historic Data

Download Data
DateValue
Dec 31, 2015 26,886.00
Sep 30, 2015 422,482.00
Jun 30, 2015 35,982.00
Mar 31, 2015 2.06 Mn
API Access

Altimmune Restructuring Costs API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=restructuring-costs&ticker=ALT&period=max&api_key=YOUR_API_KEY